A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting

Table 2 Prophylaxis duration and costs in hospital and after discharge (costs in 2010 euros)

	Days of prophylaxis duration	Non-DRG included costs (€) for prophylaxis		Source
		Enoxaparin sodium³	Rivaroxaban
	In hospital (total duration)	Costs for hospitals
MB with or without VTE¹ - after THR- after TKR	5.0 (5)5.0 (5)	0.000.00	13.0013.00	[4, 16, 27, 29]
Pre-discharge VTE without MB² - after THR- after TKR	7.0 (7)7.0 (7)	0.000.00	18.2018.20	[4, 16, 28, 29]
Post-discharge VTE or no VTE and no MB - after THR- after TKR	12.4 (32)12.7 (13)	0.000.00	32.2433.02	[4, 16, 28, 29]
	After discharge (total duration)	Costs for SHI
Post-discharge VTE or no VTE and no MB - after THR- after TKR	19.6 (32)0.3 (13)	106.621.63	134.852.06	[4, 30]

DRG = diagnosis related groups, MB = major bleeding, THR = total hip replacement, TKR = total knee replacement, VTE = venous thromboembolism, SHI = social health insurance.
¹A major bleeding event was assumed to occur on day 5 of the hospital stay and prophylaxis is stopped immediately.
²A pre-discharge VTE event was assumed to occur on day 7 after surgery and prophylaxis is stopped.
³The hospital costs for enoxaparin sodium are included in the DRGs.

ISSN: 1472-6963